CraniUS Wins FDA 510(k) Clearance for Cranial Implant

Baltimore, Maryland, September 9, 2026

FDA Clearance Advances Patient-Specific Cranial Reconstruction

The CraniUS Plate, designated NeuroPASS 1, is regulated as a Class II preformed alterable cranioplasty plate under 21 CFR 882.5320 and product code GWO. The device was reviewed by the FDA’s Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices within the Center for Devices and Radiological Health. The clearance represents a transition for CraniUS from product development to commercialization, allowing the company to make the patient-specific cranial implant available to surgeons in the U.S. The implant is designed and manufactured to match the individual patient’s cranial anatomy, providing neurosurgeons and craniofacial surgeons with a personalized reconstruction option. Cranial defects can result from traumatic injuries, tumor resection, decompressive craniectomy and other medical conditions. By tailoring the implant to each patient’s anatomy, the company aims to provide a customized approach to cranial reconstruction rather than relying solely on standardized implant configurations.

NeuroPASS Platform Builds on Cleared Implant

Beyond the cleared CraniUS Plate, the company is developing the NeuroPASS platform as a configurable cranial implant architecture. The platform is intended to support additional technologies focused on brain access, diagnostics and targeted drug delivery, subject to future regulatory requirements. According to the company, these future configurations could potentially integrate additional functions into the patient-specific cranial implant architecture. Among the programs under development are technologies intended to provide durable access to the brain, integrated sensing and diagnostic capabilities, and a fully implantable system designed for long-term targeted delivery of therapeutics from within the cranial space. The drug-delivery concept is being developed with the goal of bypassing the blood-brain barrier, which can limit the ability of some therapeutics to reach the brain. However, these programs remain investigational and are not included in the FDA-cleared CraniUS Plate.

First Commercial Product Establishes U.S. Market Entry

The FDA clearance gives CraniUS its first cleared commercial product while establishing a manufacturing and regulatory foundation for future NeuroPASS development. The company said the cleared implant provides surgeons with a patient-specific cranial reconstruction option today while creating a platform architecture that could accommodate additional technologies as individual programs progress through development and regulatory review. The company emphasized that the CraniUS Plate is cleared only for repair of cranial defects, consistent with its FDA-cleared indications for use. Future brain-access, diagnostic and therapeutic-delivery technologies are separate development programs and have not been cleared or approved by the FDA. CraniUS Therapeutics was founded in 2021 and is developing its technology around patient-specific cranial reconstruction and next-generation neurotechnology applications. The clearance marks an important medical-device regulatory milestone for CraniUS Therapeutics and provides the company with a commercial entry point for its patient-specific cranial implant technology. At the same time, the broader NeuroPASS vision remains dependent on further engineering, clinical development and applicable regulatory authorizations before additional functions can reach patients.

Source: CraniUS Therapeutics press release